MULTIDISCIPLINARY APPROACH to Oesophageal and gastric cancer



    This book aims at highlighting the present and very dynamic development in the field of pper GI cancers. Oesophageal and gastric cancer are diseases with poor prognosis. Looking back to ous efforts to treat these serious malignancies have been dated already to the ancient periods. The introductory chapter of this issue is therefore dedicated to history of gastric cancer that is tightly connected to history of development of surgical techniques. Surgery remains the basic cornerstone of the treatment of localized oesophageal and gastric cancer and chapters attributed to surgery delineate the sustained development either in classical surgical techniques but also an implementation of new technologies, especially robotic surgery into clinical practice.

    Price: 474 CZK (19EUR) - (40% discount),  Order: info@currentmedia.cz




Actual articles

Denosumab – an important part of the treatment of patients with skeletal metastatic disease

06/2020 Prof. MUDr. Samuel Vokurka, Ph.D.
Denosumab, 120 mg inj. s.c., significantly contributes to delaying the development of skeletal related events (pathological fracture, spinal cord compression, a condition requiring radiotherapy or surgery to bone) and worsening pain in patients with skeletal metastatic disease. Initial dental care with prophylactic stomatology interventions and proper supplementation of calcium and vitamin D are an integral part and condition for successful treatment with denosumab.

Benefit of the combination of encorafenib + binimetinib in the treatment of BRAF V600 mutant melanoma – updated results of the COLUMBUS study

06/2020 MUDr. Eugen Kubala
Treatment of advanced and metastatic melanoma with the BRAF V600 mutation by combination therapy with BRAF and MEK inhibitors encorafenib and binimetinib was demonstrated in the COLUMBUS study, the results of which were updated in June 2020. Encorafenib is an ATP-competitive BRAF inhibitor capable of blocking several mutated forms of BRAF kinase for 30 hours (e.g. V600E, V600D and V600K) in tumor melanoma cells against other BRAF inhibitors dabrafenib (2 hours) or vemurafenib (0.5 hours). It allows almost permanent inhibition of the mutated form of BRAF protein kinase. According to the updated results of the COLUMBUS study, the median PFS results for the combination of encorafenib + binimetinib at 14.9 months versus vemurafenib were confirmed at 7.3 months. Significant is the comparison of the two BRAF inhibitors encorafenib and vemurafenib, which indicated a higher efficacy of encorafenib versus vemurafenib median PFS 9.6 vs 7.3 months HR 0.68 (95% CI 0.52-0.88; p = 0.0038) Combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib significantly shifted the median PFS of 16.4 months and the median overall survival (OS) of 33.6 months without increasing toxicity over the established and used combinations of BRAF and MEK inhibitors used in the treatment of BRAF V600 mutant melanoma. In long-term follow-up of COMBO 450 (the combination encorafenib 450 mg and binimetinib 45 mg) vs vemurafenib (vemurafenib 960 mg) patients, 26% vs 12% of patients achieved 48-month PFS. Another primary endpoint of the COLUMBUS study was an updated outcome of OS.4-year survival was achieved in 39% of patients treated with COMBO450 combination therapy, 37% of patients treated with encorafenib 300 mg (ENCO300) monotherapy, and 26% of patients treated with vemurafenib (VEM). The updated results of the COLUMBUS study presented at ASCO (American Society of Clinical Oncology Congress) 2020 confirmed that the combination of encorafenib and binimetinib is a highly effective treatment for BRAF V600 mutant melanoma.

Hemodialysis dependent patient with relapsed acute promyelocytic leukemia treated by arsenic trioxide

06/2020 MUDr. Kateřina Benková; MUDr. Zdeněk Kořístek, Ph.D.; MUDr. Petra Richterová; MUDr. Jana Mihályová; Mgr. Dagmar Zámoravcová; Ing. Karel Lach, CSc.; prof. MUDr. Roman Hájek, CSc.
Arsenic trioxide (ATO) is a drug of choice in the treatment of relapsed acute promyelocytic leukemia (APL). Guidelines for the treatment of hemodialysis dependent patients with APL do not exist. Here we describe the treatment of relapsed APL in a hemodialysis dependent patient by ATO at the dose of 10 mg three times a week after hemodialysis with frequent monitoring of laboratory values and QT interval. Molecular remission was achieved without serious adverse events. The authors further discuss the use of ATO in hemodialysis dependent patients and conclude, that ATO can be safely and effectively used in such patients under the condition of close monitoring of toxicity and adverse events; assessment of the arsenic concentration in blood is not useful for treatment management.